Turmeric Effect on Reduction of Serum Prolactin and Related Hormonal Change and Adenoma Size in Prolactinoma Patients


Lead Sponsor: Mashhad University of Medical Sciences

Source Mashhad University of Medical Sciences
Brief Summary

Prolactinoma is the most prevalent anterior hypophysis tumor. The principal treatment for this disorder is Dopamine agonist drugs including bromocriptin and Cabergoline. However, 50% of Bromocriptin treated and 17% of Cabergoline treated patients are resistant to these drugs. Curcumin is the main derivative of turmeric ,an old spice which is used frequently in Indian and Iranian cuisine. It has been proved that curcumin can reduce mammotrope cells proliferation and also intracellular hormone production. The purpose of this study is to evaluate the effect of turmeric on prolactinoma patients.

Overall Status Unknown status
Start Date 2011-07-01
Completion Date 2012-08-01
Primary Completion Date 2012-07-01
Phase Phase 1
Study Type Interventional
Primary Outcome
Measure Time Frame
serum prolactin level 2weeks and one month after treatment
Secondary Outcome
Measure Time Frame
change in LH,FSH and estradiol from baseline one month ofter treatment
Enrollment 30

Intervention Type: Drug

Intervention Name: Curcumin

Description: Curcumin is prescribed to new cases of hyperprolactinoma



Inclusion Criteria: - hyperprolactinemia - microprolactinoma Exclusion Criteria: - pregnancy - macroadenoma - neurologic signs due to tumor



Minimum Age:

20 Years

Maximum Age:

45 Years

Healthy Volunteers:


Overall Contact Contact information is only displayed when the study is recruiting subjects.
Facility: Status: Contact: Mashad University of Medical Sciences haleh rokni 00985118012976 [email protected]
Location Countries

Iran, Islamic Republic of

Verification Date


Responsible Party

Type: Principal Investigator

Investigator Affiliation: Mashhad University of Medical Sciences

Investigator Full Name: Haleh Rokni Yazdi

Investigator Title: assisstant professor

Has Expanded Access No
Study Design Info

Allocation: N/A

Intervention Model: Single Group Assignment

Primary Purpose: Treatment

Masking: None (Open Label)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hyperprolactinoma

Clinical Trials on Curcumin